Navigation Links
Positive results from placebo-controlled phase IIa study in,patients suffering from house dust mite allergy

G10 is currently being studied in clinical trials for the treatment of
allergic rhinitis and atopic dermatitis.

About allergic diseases
Allergy as a whole is a multi-faceted disease and clinically manifests in various allergic disorders
including allergic rhinitis, asthma, atopic dermatitis and food hypersensitivity. It is an exaggerated
reaction by the patient’s immune system to a normally harmless substance such as various
environmental proteins present in pollen, dust mite faeces, or food. According to the World Health
Organization, more than 20% of the world population suffers from allergic diseases (WHO, 2002).
Allergy to house dust mites is one of the most common causes of allergic disease worldwide and it is
estimated that nearly 50% of allergic people are sensitized to dust mite allergens (Clin Exp Allergy,
2004;34:597). Dust mite allergy frequently starts with symptoms of rhinitis, but over the longer term
many patients may develop symptoms of asthma. Today, three general approaches are commonly
being pursued to relieve the symptoms of allergic diseases: avoidance of the allergen, prescription of
medication that targets disease symptoms, and conventional immunotherapy, also known as
desensitization. The latter is the only disease-modifying treatment available, however, it is timeconsuming
(3-5 years) and inconvenient for the patients. Therefore, a significant unmet medical
need remains for allergic disease treatment.


For further information please contact:
Cytos Biotechnology AG, Wagistrasse 25, CH-8952 Schlieren
Claudine Blaser, PhD
Director Corporate Communications
Tel.: +41 44 733 47 20
e-Mail: claudine.blaser@cytos.com
Webseite: www.cytos.com

About Cytos Biotechno
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
(Date:5/4/2015)... BUFFALO, N.Y. , May 4, 2015 /PRNewswire/ ... Stephanie Englert , PharmD, has completed preliminary analysis ... Disorder and Schizophrenia. Resources from Clinical Support Services, ... Medication Reviews (CMR) with patients currently taking psychiatric ... events. The research found that 93% of patients ...
(Date:5/4/2015)... 4, 2015 MEI Pharma, Inc. (Nasdaq: ... the clinical development of novel therapies for cancer, ... of the Company,s investigational drug candidate ME-344 in ... combined with a tyrosine-kinase inhibitor (TKI). In addition, ... a potent inhibitor of mitochondrial oxidative phosphorylation (OXPHOS) ...
(Date:5/4/2015)... , May 4, 2015  Geneia, a company ... technology solutions to improve healthcare efficiencies, today announced ... Rehabilitation Center (BNRC) use Geneia,s advanced analytics ... improve the quality and lower the cost of ... clinical, outcomes, claims and utilization data from multiple ...
Breaking Medicine Technology:Clinical Support Services, Inc. Verifies That Increased Availability of MTM Services Facilitates Identification of Adverse Drug Effects in Psychiatric Patients 2Clinical Support Services, Inc. Verifies That Increased Availability of MTM Services Facilitates Identification of Adverse Drug Effects in Psychiatric Patients 3MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 2MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 3MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 4MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 5Geneia Launches First-of-its-Kind Partnership to Use Advanced Analytics to Improve the Quality and Cost of Care for Skilled Nursing and Rehabilitation Patients 2Geneia Launches First-of-its-Kind Partnership to Use Advanced Analytics to Improve the Quality and Cost of Care for Skilled Nursing and Rehabilitation Patients 3
... Mylan Inc. (Nasdaq: www.mylan.com . ... release includes statements that constitute "forward-looking statements." These statements ... the Private Securities Litigation Reform Act of 1995. Because ... results may differ materially from those expressed or implied ...
... 6 Endo Pharmaceuticals (Nasdaq: ENDP ) today ... Specialty Pharmaceuticals Conference on Thursday, August 12, 2010 , at 8:00 ... Endo, will review the company,s products and development programs. , ... The presentation will be webcast live and can ...
Cached Medicine Technology:Endo to Present at the Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference 2
(Date:5/4/2015)... (PRWEB) May 04, 2015 Malibu ... oral antiseptic breath spray. KissSafe™ is the first ... a safer experience while adding fresh breath appeal. ... and effectively kills germs in the mouth and ... also contains ingredients that possess additional wellness benefits. ...
(Date:5/4/2015)... May 04, 2015 Milton Hershey School® ... 2015 Alumnus of the Year, recognizing his commitment to ... philanthropy he sets for MHS students. , “Dr. Graves ... happen when children are provided a top-notch education, a ... their passions,” said Pete Gurt ’85, president of MHS. ...
(Date:5/4/2015)... Johnson & Wales University (JWU) held a groundbreaking ceremony ... on Wednesday, April 22. , Johnson & Wales becomes the ... the re-alignment of Interstate-195. JWU’s new academic building, which will ... in Providence, is scheduled to be completed in July 2016. ... university purchased in 2012. , “It has long been our ...
(Date:5/4/2015)... The opportunity for children to dream of a ... forces behind The Fairy Godmother Next Door, a new children’s ... Stark. , The inspiration for the enchanting story of a ... Stark’s desire to be a fairy godmother. , “My wish ... my neighbors’ children since they were born. We discuss fairies ...
(Date:5/4/2015)... Now in its seventh year, the IPC ... made outstanding contributions to the company, to their facilities ... and post-acute care settings. The five award categories are: ... Year, Advanced Practice Clinician of the Year, Newcomer Provider ... Recipients are selected by IPC’s senior management team. , ...
Breaking Medicine News(10 mins):Health News:80 Million Germs from Kissing - Introducing KissSafe™ 2Health News:Milton Hershey School Names 2015 Alumnus of the Year 2Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 2Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 3Health News:Introducing New Children’s Book The Fairy Godmother Next Door 2Health News:IPC Healthcare Announces Clinicians of the Year 2Health News:IPC Healthcare Announces Clinicians of the Year 3
... Increased 15%; Online Ad Revenue Increased 21%WebMD Achieves ... and 1.3 Billion Quarterly Page ViewsNEW YORK, Feb. ... WBMD ) today announced financial results for the ... results confirm WebMD,s market leadership in a challenging ...
... Feb. 19 Covance Inc. (NYSE: CVD ) ... D., to its Board of Directors. Dr. Sheares is former ... of Reliant Pharmaceuticals, Inc., a pharmaceutical company that marketed a ... was president of the U.S. Human Health division of Merck ...
... prove cause and effect, researcher says , , THURSDAY, Feb. ... fast-food joints could increase your risk for stroke by ... restaurants are less plentiful, a new study suggests. , ... known, though, said study author Dr. Lewis B. Morgenstern, ...
... Netherlands, Feb. 19 A BioPharma Pavilion at CPhI ... P-MEC Japan will be ... Japan ,s leading pharma services events by UBM International Media. ... completed by the contract services event ICSE Japan -- will be ...
... statins, used by millions of Americans to treat ... according to researchers at Texas Health Presbyterian Hospital ... the influence of statin drugs," appears in the ... make quicker, more accurate diagnoses of suspected thyroid ...
... monitoring can keep problem from advancing, experts say , , THURSDAY, ... levels causes poorer brain function in people with type 2 ... aged 55 and older at 52 sites in Canada and ... a larger study on cardiovascular risk in diabetes, underwent cognitive ...
Cached Medicine News:Health News:WebMD Announces Fourth Quarter Financial Results 2Health News:WebMD Announces Fourth Quarter Financial Results 3Health News:WebMD Announces Fourth Quarter Financial Results 4Health News:WebMD Announces Fourth Quarter Financial Results 5Health News:WebMD Announces Fourth Quarter Financial Results 6Health News:WebMD Announces Fourth Quarter Financial Results 7Health News:WebMD Announces Fourth Quarter Financial Results 8Health News:WebMD Announces Fourth Quarter Financial Results 9Health News:WebMD Announces Fourth Quarter Financial Results 10Health News:WebMD Announces Fourth Quarter Financial Results 11Health News:WebMD Announces Fourth Quarter Financial Results 12Health News:WebMD Announces Fourth Quarter Financial Results 13Health News:WebMD Announces Fourth Quarter Financial Results 14Health News:WebMD Announces Fourth Quarter Financial Results 15Health News:WebMD Announces Fourth Quarter Financial Results 16Health News:WebMD Announces Fourth Quarter Financial Results 17Health News:WebMD Announces Fourth Quarter Financial Results 18Health News:WebMD Announces Fourth Quarter Financial Results 19Health News:Covance Elects Bradley T. Sheares to Company's Board of Directors 2Health News:More Fast-Food Joints in Neighborhoods Mean More Strokes 2Health News:New Features for 2009 Japan Events 2Health News:New Features for 2009 Japan Events 3Health News:Dallas Scientists Discover Statins May Falsely Indicate Thyroid Problems 2Health News:Out-of-Control Blood Sugar May Affect Memory 2
400 Series Monopolar Foot Activated Forceps...
Dissecting Forceps, straight, with RF-cable, 7" (18 cm). For use with all electrosurgical generators with standard three-prong sockets....
Extended blade - 25/box....
... In the way it implements the ... 510 Meta system is unmatched. It allows ... compromising resolution and efficiency. Unprecedented flexibility for ... functions that guarantee fast and efficient structural ...
Medicine Products: